CASExGLOBAL announced a groundbreaking partnership with Clinical AI and iOR Partners to introduce the first-ever AI-powered SMO bringing decentralized clinical trials to ophthalmic OBS centers, a revolutionary move for the industry. iOR Partners develops OBS suites nationwide and Clinical AI specializes in the application of artificial intelligence in healthcare and life sciences.
Under the leadership of renowned retina specialist Dr. David RP Almeida, this initiative brings together artificial intelligence and a decentralized trial framework, designed to streamline processes, enhance patient safety, and accelerate drug and device development.
In addition to the innovation of AI-powered systems, iOR Suites undergo a rigorous accreditation process, making them ideal for decentralized clinical trials.
Their robust accreditation framework ensures that sites meet high standards of quality and performance, further reinforcing the value of this new partnership.
Both companies will showcase their capabilities at the annual American Academy of Ophthalmology meeting in Chicago, October 19-21.
“Our top priority has always been patient safety and scientific integrity,” said David RP Almeida, MD, MBA, PhD, founder of CASExGLOBAL. “The OBS model we’ve developed at Erie Retina Research is the most efficient way to operate an ophthalmology focused clinical research site, accelerating the pace of research while prioritizing patient safety and experience. This model is ready to grow; and with iOR Partners and Clinical AI, we are ready to bring our novel model and proven strategies to the 130+ iOR Suites around the world.”
Tony Burns, founder and chief strategy officer of iOR Partners, highlighted the strength of their existing surgeon network, adding: “Our network of iOR Suites is already accustomed to going through extensive steps to become accredited, which lends itself perfectly to decentralized trials. With our broad surgeon network and the ability to work directly with sponsors, we will roll out unique strategies that will redefine clinical research across ophthalmology.”
Alex Ravitz, chief operating officer of Clinical AI spoke about AI’s impact, stating: “At Clinical AI, we are pioneering the use of artificial intelligence in healthcare in areas such as streamlining clinical trials. Our platforms allow trials to move faster while maintaining high data quality, shortening the time it takes for new medical products to receive regulatory approvals.”
Hamza Hasan, CEO of Clinical AI on the synergistic partnership: “This collaboration between CASExGLOBAL, Clinical AI, and iOR positions CASEx@iOR at the forefront of clinical trial innovation, with plans to expand these decentralized, AI-powered trials to a global scale. Together, we are enabling faster, safer, and more efficient clinical trials directly in collaboration with sponsors, offering unmatched reach and innovation.”
About CASExGLOBAL
CASExGLOBAL is a leader in ophthalmology innovation, providing access to top retina surgeons for mentoring, research, and education. Through partnerships with pharmaceutical companies and advanced training centers, CASExGLOBAL helps pioneer new surgical techniques and clinical trials in ophthalmology. Their state-of-the-art labs offer surgeons hands-on experience using ‘near real surgical specimens.’
About Clinical AI
Clinical AI is a technology company specializing in the application of artificial intelligence in healthcare and life sciences. Their MAIA (Medical AI Assistant)™ platform has a broad range of applications from clinical trial eligibility screening to virtual AI assistants trained on clinical trial protocols. Clinical AI helps sponsors, CROs, hospitals, and individual physicians bring life-saving treatments to patients quicker and more efficiently, leading the way in AI-driven innovations in healthcare.
About iOR Partners
iOR Partners is the leader in office-based surgery (OBS) innovation and is paving the way for the future of ophthalmic surgery with OBS suites. iOR Suites integrate clinic and surgery in one location to increase surgeons’ flexibility and improve the patient experience while providing the highest level of safety. With a broad surgeon network and patient-centered approach, iOR Partners is reshaping ophthalmic surgery and clinical trial design and execution globally.